Oveporexton, a narcolepsy drug with a mechanism no controlled substance shares, goes into Schedule IV
The Drug Enforcement Administration has placed oveporexton, a new narcolepsy medicine, in Schedule IV. The rule took effect on November 12, 2026[1]. FDA approved the drug, sold as Orzeyful, on August 5, 2026, for adults with narcolepsy type 1[1], and DEA's rule places it in Schedule IV with its salts and isomers[1].
A new kind of wakefulness drug. Oveporexton, developed by Takeda as TAK-861[1], switches on the orexin type 2 receptor, part of the brain's wakefulness system. Nothing else in the Controlled Substances Act works that way[1].
Why Schedule IV. In the human abuse study, experienced stimulant users liked high doses of oveporexton about as much as phentermine, the Schedule IV diet stimulant[1]. In trials, the most common abuse-related side effect in people without narcolepsy was euphoric mood[1]; in patients with narcolepsy type 1 at the approved doses such effects were infrequent[1]. It has no street presence: DEA's forensic lab data show no law-enforcement encounters of it in the United States[1].
How it was scheduled
This is the expedited path Congress set for newly approved medicines. The rule is an interim final rule, effective at once, with comments taken afterwards[1]. Comments are due by December 14, 2026[1], under Docket No. DEA-1775[1].
References
- Schedules of Controlled Substances: Placement of Oveporexton in Schedule IV — Federal Register
Comments
Sign in to join the conversation.
No comments yet.